Author:
Damane Botle Precious,Mulaudzi Thanyani,Motloba Oratile,Bester Janette,Demetriou Demetra,Ledet Elisa Marie,Dlamini Zodwa
Publisher
Springer Nature Switzerland
Reference80 articles.
1. Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017). Emerging proteomics biomarkers and prostate cancer burden in Africa. Oncotarget, 8, 37991–38007.
2. Anassi, E., & Ndefo, U. A. (2011). Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P and T, 36, 197–202.
3. Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., & Alanko, T. (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. Journal of Clinical Oncology, 38, 395.
4. Antony, J. V. M., Ramani, P., Ramasubramanian, A., & Sukumaran, G. (2021). Particle size penetration rate and effects of smoke and smokeless tobacco products - An invitro analysis. Heliyon, 7, e06455.
5. Banchereau, R., Leng, N., Zill, O., Sokol, E., Liu, G., Pavlick, D., Maund, S., Liu, L.-F., Kadel, E., Baldwin, N., Jhunjhunwala, S., Nickles, D., Assaf, Z. J., Bower, D., Patil, N., Mccleland, M., Shames, D., Molinero, L., Huseni, M., Sanjabi, S., Cummings, C., Mellman, I., Mariathasan, S., Hegde, P., & Powles, T. (2021). Molecular determinants of response to PD-L1 blockade across tumor types. Nature Communications, 12, 3969.